甘李藥業(603087.SH):現階段公司正積極開展適應症為2型糖尿病(T2DM)、肥胖及超重體重管理的Ⅱ期臨牀試驗
格隆匯8月9日丨有投資者向甘李藥業(603087.SH)提問,“公司目前研發的GLP-1研發進展如何?和同業公司對比產品亮點是什麼?”
公司回覆稱,公司在研的1類創新型治療用生物製品GZR18是一種預期每一週注射一次長效胰高血糖素樣肽-1(GLP-1)受體激動劑類藥物,已獲批臨牀的適應症為成人2型糖尿病、肥胖/超重體重管理。公司深耕於代謝疾病領域25年,在設計開發GZR18產品時,做了大量真實世界市場的調研,走到臨牀和患者中去,瞭解患者需求,並融入到產品設計和開發中,藥物的安全性和有效性(長效、優效)作為首要考慮的問題,我們希望做出真正有差異化的產品。現階段公司正在積極開展適應症為2型糖尿病(T2DM)、肥胖及超重體重管理的Ⅱ期臨牀試驗。該產品是中國首款與司美格魯肽頭對頭評估藥物有效性的GLP-1受體激動劑,公司將療效設置為主要終點。下一階段我們將持續推動研發成果儘快落地,以增加新的盈利點。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.